Revvity stock hits new 52-week high as gains extend
Published on 08/20/2026 at 18:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revvity Inc. (US76155R1086) stock pushed to a fresh 52-week high in August 2026, with one market report citing an intraday peak of $122.26 and a last traded level of $122.10 that values the life sciences and diagnostics group at $13.52 billion as of August 20, 2026. A separate performance overview notes that the shares have delivered a 24% gain year to date and a 19% advance over the past six months, underscoring sustained momentum through mid-2026. For investors, the 52-week high aligns with a period of sector strength and renewed appetite for diagnostic and research tools providers.
Momentum builds after August price jump
Market commentary dated August 19, 2026 highlights that Revvity shares rose 5.0% on that session to a closing price of $119.45, trading between a 52-week low of $81.22 and a then recent high of $122.11. That same snapshot notes that the 5.0% one-day move came as the stock pushed to the upper end of its 52-week range, suggesting that the August rally has been concentrated in the top third of its trailing-year band. A broader sector wrap published for August 19, 2026 points out that Revvity was among healthcare names advancing more than 4% on the day, reinforcing that the stock participated in a wider move in life science tools and diagnostics.
Valuation metrics from the same August 19, 2026 assessment show Revvity trading at a level described as 1.6% over an intrinsic value estimate, with the market price of $119.45 compared against a fair value gauge of $117.56. The analysis characterizes this premium as modest, signaling that the stock is not dramatically extended relative to that particular valuation framework. Taken together with the new 52-week high of $122.26 reported on August 20, 2026, the data implies that Revvity has added roughly $2.81 per share, or 2.4%, on top of an already extended August 19 close to set the fresh high.
Analyst framework and market positioning
An institutional holding disclosure circulated on August 20, 2026 notes that Revvity stock opened a recent session at $119.33, illustrating that the latest climb to $122.26 has taken place over a short span of trading. The same overview cites a consensus stance described as a Hold rating and an average price target of $108.36, implying that the current spot price of around $122 is more than $13 above that target. In percentage terms, that places the market level roughly 12% higher than the average target, a gap that signals how rapidly sentiment and price have moved ahead of earlier expectations.
A separate quantitative stock report dated August 19, 2026 lists a current price reference of $119.45 alongside a revised target of $119.00, indicating that the shares have reached and then exceeded that framework in the latest session. Within that same material, Revvity is described as a global life sciences and diagnostics company that was formed in 2023 following the rebranding of PerkinElmer, so investors are effectively evaluating a relatively new branded entity with a longer operating heritage. Another capital markets overview for August 20, 2026 places Revvity in the S&P 500 peer set with a market capitalization figure in the low-teens billions of dollars, consistent with other mid-cap healthcare tools and diagnostics names.
Across these various assessments, one analytical model assigns Revvity a composite quality and growth score of 78 on its scale, grouping the company among higher-quality mid-cap names in its sector. The same model uses the $119.45 price and the $117.56 fair value gauge to conclude that the shares are somewhat overvalued, even as the overall score suggests solid fundamentals. For investors, the quantified takeaway is that August 2026 price action has moved faster than consensus and model-based estimates, with the stock now trading above both the $108.36 average target and the $119.00 quantitative objective while also sitting 1.6% above the model fair value.
Diagnostics and life sciences platforms
Revvity focuses on supplying diagnostic tests, imaging systems, reagents and analytical instruments that are used in areas such as prenatal and newborn screening, infectious disease testing, oncology, and research into genetic and metabolic disorders. Its diagnostics portfolio is designed to support early disease detection and monitoring, helping healthcare providers to improve patient outcomes through more targeted treatment decisions. Alongside clinical diagnostics, Revvity delivers life science research tools and services used by pharmaceutical and biotechnology companies in drug discovery, screening, and translational research workflows.
In addition to instruments and reagents, Revvity offers software and informatics solutions that allow laboratories to manage data, automate workflows, and interpret complex results from high-throughput experiments. The company also operates service operations that provide maintenance, training, and technical support for installed systems, creating recurring revenue streams beyond the initial equipment sale. Collectively, these product and service lines position Revvity as a diversified supplier across both regulated clinical markets and research-driven environments, which can help balance revenue exposure across economic cycles and funding trends.
Revvity stock at a fresh high
As of the latest August 20, 2026 quote snapshots, Revvity stock is trading slightly below its intraday peak, with one intraday report placing the last traded price at $122.10 and the intraday high at $122.26. That price compares with the August 19, 2026 close of $119.45, representing a gain of $2.65, or 2.2%, across the most recent completed and ongoing sessions referenced in available data. In market capitalization terms, the $122.10 price and reported share count translate into a value of $13.52 billion, placing Revvity firmly within the mid-cap segment of the U.S. healthcare sector.
From a trailing performance perspective, the same August 20, 2026 overview that cites the 52-week high of $122.26 also reports a 24% return year to date and a 19% advance over the past six months. Those figures indicate that most of the stock's appreciation has occurred in the first eight months of 2026, with a meaningful portion concentrated in the more recent half-year window. With the shares now hovering close to both the $122.26 52-week high and the $122.11 high marked a day earlier, investors are watching whether Revvity can consolidate above the previous resistance zone defined by the low $120s.
Read more
A market report on Revvity's new 52-week high provides detailed intraday context on the $122.26 peak, $122.10 last price, and the 24% year-to-date return figure as of August 20, 2026. For investors comparing valuation and quality metrics, an analytical overview using a GF Score of 78 outlines why some models currently classify the stock as 1.6% overvalued at $119.45 relative to a fair value estimate of $117.56. A recent institutional ownership update also summarizes consensus rating data and an average price target of $108.36, which now lags the latest spot price by a double-digit percentage margin.
Fact box
Revvity Inc. stock profile
Company: Revvity Inc.
ISIN: US76155R1086
Ticker: RVTY
Exchange: U.S. listing in the healthcare sector
Market cap: $13.52 billion (as of August 20, 2026)
Sector / Industry: Healthcare - life sciences tools and diagnostics
Index membership: S&P 500 constituent based on recent market-data classifications
